A comparison of monoclonal antibodies against murine PD-1 and PD-L1

Abstract

Abstract Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAb) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat anti-mouse mAbs have been used to model cancer immunotherapy in mouse models. We set forth the amino acid sequences of mAbs specific for mouse PD-1 (29F.1A12) and PD-L1 (10F.9G2) and compare their avidities, blocking capacities, biological activities, and epitope recognition with other commonly used mAbs. Of note, we found that 29F.1A12 had an approximately 100-fold better affinity and blocking capacity than RMP1-14. Further manipulation of these sequences should facilitate better modeling of immunotherapy in mouse models and the generation of novel agents. Supported by grants from the National Institutes of Health (P01 AI56299 and P01 CA236749).